MedTrace Logo

13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients

NCT02492438 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2015-07-08

No results posted yet for this study

Summary

To assess the immunogenicity of the PCV13 (13 valent pneumococcal conjugated vaccine) vaccine as compared to the PPV23 (23 valent pneumococcal polysaccharide vaccine) vaccine in patients treated with chronic hemodialysis that are pre-immunized with the PPSV23 vaccine or are PPV23 vaccine naïve by measuring the ELISA and OPA (opsonophagocytic assay) titers after 4 and 52 weeks.

Conditions

  • Chronic Kidney Failure

Interventions

BIOLOGICAL

PPV23 vaccination or PCV13 vaccination

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • AZ Sint-Jan AV

    lead OTHER

Principal Investigators

  • Stefaan J Vandecasteele, MD, PhD · Department of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge, Belgium

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-02-28
Completion
2014-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02492438 on ClinicalTrials.gov